MedTrace Logo

Psoriatic Arthritis Treat to Target vs. Usual Care

NCT01692912 · Status: WITHDRAWN · Phase: NA · Type: INTERVENTIONAL

Last updated 2017-04-07

No results posted yet for this study

Summary

Canadian Rheumatologists will be randomized to treat their participants with active Psoriatic Arthritis to a target (disease activity score \<2.6), or as per their routine care. The aim of this study is to determine whether treating to a target results in greater disease improvement than treating patients using routine care.

Conditions

  • Psoriatic Arthritis (PsA)

Interventions

OTHER

Intensive Care

Rheumatologist aims to treat participant in order to achieve a disease activity score improvement of DAS28\<2.6

Sponsors & Collaborators

  • Amgen

    collaborator INDUSTRY

  • Pope Research Corporation

    lead INDUSTRY

Principal Investigators

  • Janet E. Pope, MD, MPH, FRCPC · Pope Research Corp., University of Western Ontario, St. Joseph's Health Care London

Study Design

Allocation
RANDOMIZED
Purpose
SUPPORTIVE_CARE
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-10-31
Primary Completion
2014-11-30
Completion
2014-11-30

Countries

  • Canada

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01692912 on ClinicalTrials.gov